Roche strikes quantum computing deal to develop early-stage Alzheimer’s drugs with CQC
Swiss pharma giant Roche is to develop quantum algorithms to help it discover and develop early-stage drugs as part of a deal with Cambridge Quantum Computing (CQC).The company is planning to use CQC’s quantum chemistry platform, EUMEN, to design and implement noisy-intermediate-scale-quantum (NISQ) algorithms for early-stage drug discovery, particularly for the treatment of Alzheimer’s Disease.An early step in the fight against dementiaWhile the CQC deal will be focused on speeding up the discovery process for drugs to help treat Alzheimer’s, it will likely be expanded in scope should it prove successful.“For many years quantum computing has held out great promise for discovering new therapeutics that aid humanity in fighting some of the most devastating and damaging diseases. We are pleased that due to the careful and pioneering efforts...
